Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients

Eur J Gynaecol Oncol. 2004;25(3):321-3.

Abstract

Introduction: The aim of this study was to evaluate endometrial changes after five years of tamoxifen treatment by measuring endometrial thickness with transvaginal ultrasonography.

Materials and methods: Fifty-five asymptomatic postmenopausal women who had assumed tamoxifen, 20 mg daily, for five years were controlled six months after discontinuation of the therapy. Of these 42 were followed-up at 12 months. Statistical analysis was performed using the analysis of variance for repeated measures and the Anova test; p < 0.05 was considered statistically significant.

Results: We found a significant reduction in endometrial thickness at six months (p = 0.0046) and at 12 months (p = 0.0003) but not between six and 12 months (p = 0.06).

Conclusion: A statistically significant reduction in endometrial thickness after discontinuation of tamoxifen therapy was found. This can probably be attributed to the cessation of the estrogenic side-effects of tamoxifen therapy.

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Endometrium / diagnostic imaging*
  • Endometrium / drug effects
  • Endometrium / pathology
  • Female
  • Humans
  • Middle Aged
  • Postmenopause
  • Selective Estrogen Receptor Modulators / administration & dosage*
  • Tamoxifen / administration & dosage*
  • Ultrasonography

Substances

  • Selective Estrogen Receptor Modulators
  • Tamoxifen